Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Total Revenue
1,704,048
1,491,212
1,313,646
1,116,854
Cost of Revenue
359,466
315,264
241,786
209,620
Gross Profit
1,344,582
1,175,948
1,071,860
907,234
Operating Expenses
Research Development
715,007
696,328
610,753
661,905
Selling General and Administrative
680,924
604,353
554,336
476,593
Non Recurring
--
--
--
--
Others
74,108
48,791
46,471
(26,953)
Total Operating Expenses
1,470,039
1,349,472
1,211,560
1,111,545
Operating Income or Loss
(125,457)
(173,524)
(139,700)
(204,311)
Income from Continuing Operations
Total Other Income/Expenses Net
31,358
51,652
131,679
(594,727)
Earnings Before Interest And Taxes
(73,382)
(102,651)
3,107
(794,918)
Interest Expense
21,429
40,054
38,982
36,132
Income Before Tax
(94,811)
(142,705)
(35,875)
(831,050)
Income Tax Expense
(70,963)
(65,494)
81,167
(200,840)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(23,848)
(77,211)
(117,042)
(630,210)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(23,848)
(77,211)
(117,042)
(630,210)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(23,848)
(77,211)
(117,042)
(630,210)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information